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The kappa-opioid receptor (KOR) / dynorphin system is implicated with behavioral and
neurobiological effects of stress exposure (including heavy exposure to drugs of abuse) in
translational animal models. Thus some KOR-antagonists can decrease the aversive,
depressant-like and anxiety-like effects caused by stress exposure. The ﬁrst generation of
selective KOR-antagonists have slow onsets (hours) and extremely long durations of action
(days-weeks), in vivo. A new generation of KOR antagonists with rapid onset and shorter
duration of action can potentially decrease the effects of stress exposure in translational
models, and may be of interest for medication development. This study examined the rapid
onset anti-stress effects of one of the shorter acting novel KOR-antagonists (LY2795050,
(3-chloro-4-(4-(((2S)-2-pyridin-3-ylpyrrolidin-1-yl)methyl) phenoxy)benzamide)) in a singlesession open space swim (OSS) stress paradigm (15 min duration), in adult male and
female C57BL/6 J mice. LY2795050 (0.32 mg/kg, i.p.) had rapid onset (within 15 min) and
short duration (<3 h) of KOR-antagonist effects, based on its blockade of the locomotor
depressant effects of the KOR-agonist U50,488 (10 mg/kg). LY2795050 (0.32 mg/kg),
when administered only 1 min prior to the OSS stress paradigm, decreased immobility in
males, but not females. With a slightly longer pretreatment time (15 min), this dose of
LY2795050 decreased immobility in both males and females. A 10-fold smaller dose of
LY2795050 (0.032 mg/kg) was inactive in the OSS, showing dose-dependence of this
anti-stress effect. Overall, these studies show that a novel KOR-antagonist can produce
very rapid onset anti-immobility effects in this model of acute stress exposure.
Keywords: open space swim, kappa-opioid receptor, stress, acute stress disorder, dynorphin

Abbreviations: 95%CI, 95%conﬁdence interval; FST, Forced swim test; DOR, delta-opioid receptor; KOR, kappa-opioid
receptor; MOR, mu-opioid receptor; LY, LY2795050 (short-acting KOR antagonist); NS, non-signiﬁcant; OSS, Open space
swim; PT, pretreatment.
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INTRODUCTION

modiﬁcation of the FST assay is the open space swim (OSS)
stress model, which due to its substantially greater available swim
area, allows observation of more adaptive swim behaviors (Stone
et al., 2008; Lin et al., 2011; Cates et al., 2013). In this study, we
used a 1-day OSS procedure to examine in greater detail the rapid
onset anti-stress effects of the KOR-antagonist LY2795050, as
well as a follow-up to previously reported KOR-antagonist sex
differences for the FST test (Laman-Maharg et al., 2018; Butelman
et al., 2021).

Acute stress exposure can cause behavioral and neurobiological
changes (Reed et al., 2012; Carter et al., 2020; Varlinskaya et al.,
2020; Becker et al., 2021), and can result in psychiatric sequeleae
in humans, including acute stress disorder. The κ(kappa)-opioid
receptors (KOR) and their endogenous ligands, the dynorphins,
are one of the systems implicated in behavioral and
neurobiological effects of stress exposure (Shirayama et al.,
2004; Knoll and Carlezon, 2010; Reed et al., 2012; Chavkin,
2018). Thus, several studies have shown that the earliest
known
selective
KOR-antagonists,
including
norbinaltorphimine (nor-BNI), decreased immobility in the
standard forced swim test (FST), as well as other behavioral
consequences of stress exposure (Portoghese et al., 1987; Zhang
et al., 2007; Carroll and Carlezon, 2013; Falcon et al., 2014).
However, some of these early selective KOR-antagonists, such as
nor-BNI, have slow onsets of action (e.g., several hours), and
extremely long-lasting proﬁles in vivo (days-weeks, depending on
the assay) (Horan et al., 1992; Broadbear et al., 1994; Butelman
et al., 1998; Carroll and Carlezon, 2013). This may complicate
their use in translational models of acute stress exposure and its
consequences, and eventual medication development (Carroll
and Carlezon, 2013; Page et al., 2019).
Several chemically unrelated shorter-acting KOR-antagonists
have been developed more recently, and some have reached the
clinical investigation stage (Aldrich et al., 2009; Chang et al., 2011;
Rorick-Kehn et al., 2014; Huang et al., 2016; Valenza et al., 2017;
Guerrero et al., 2019; Margolis et al., 2020; Valenza et al., 2020).
We recently reported that one of the shorter acting KORantagonists, LY2795050, produced anti-immobility effects in
the forced swim test (FST) in male, but not female, mice
(Butelman et al., 2021). This is consistent with a sex difference
observed with nor-BNI in the same assay (Laman-Maharg et al.,
2018). Of translational relevance, 11C-LY2795050 has been used
as a KOR positron emission tomography radiotracer in humans
(Naganawa et al., 2015; de Laat et al., 2019), and is also
structurally related to LY2456302 (aticaprant, CERC-501),
which has reached the clinical investigation stage (Lowe et al.,
2014; Reed et al., 2017). LY2795050 exhibits selectivity for KOR
over mu-opioid and delta-opioid receptors (MOR and DOR)
(Zheng et al., 2013). Thus, in cloned human receptors, the afﬁnity
(Ki) of LY2795050 for KOR, MOR and DOR is 0.72, 25.8 and
153 nM respectively (Zheng et al., 2013). The antagonist potency
of LY2795050 in vitro (Kb) at KOR, MOR and DOR is 0.63, 6.8
and 83.3 nM respectively (Zheng et al., 2013).
The FST was originally developed as a screening test for antidepressants, and its mechanistic underpinnings and
interpretation have been extensively discussed (Porsolt et al.,
1977; Porsolt et al.,1978; Chen et al., 2015; Molendijk and de
Kloet, 2019; Armario, 2021). Recent reviews conclude that
increased immobility in swim stress assays is reﬂective of a
transition from active to passive coping, in the face of an
inescapable stressor (Lanius et al., 2018; Molendijk and de
Kloet, 2019; Armario, 2021). Several authors have also found
that greater swim area allows more adaptive swimming behaviors
for study (Jacobson M. L. et al., 2020; Armario, 2021). One
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METHODS
Subjects: Mouse studies were approved by the Rockefeller
University Animal Care and Use Committee, consistent with
the Guide for the Care and Use of Animals (National Academy
Press; Washington, DC). Adult (9–10 weeks of age upon arrival to
the facility), gonadally intact C57BL/6 J male and female mice
were purchased from the Jackson Laboratory. The facility was
approved by the American Association for Accreditation of
Laboratory Animal Care (AAALAC). Mice were housed in one
room at least 7 days prior to experiments. Mice were housed in
same-sex groups (two to four per cage), in transparent plastic
shoebox cages (19.6 cm wide X 30.9 cm long X 13.3 cm tall;
Thoren Caging Systems, Hazleton, PA, United States). A n  8
was the standard group size; this could vary slightly due to the
availability of mice per cage. The cages had corncob bedding
(“Bed-o’Cobs”, the Andersons, Maumee, OH, United States);
shredded paper was added for nesting. The room was
maintained at controlled temperature (≈20–22°C) and
humidity, and had a 12:12 light:dark cycle (lights on at 0700),
with overhead lighting. Experimental procedures occurred in the
same room as housing. Procedures took place between 09:00 and
13:00 h.

Apparatus
Locomotor activity: Locomotor activity was examined in mice
placed individually in rectangular transparent plastic cages
(19.7 cm width × 41.3 cm length × 20.3 cm height). Each bin
had bedding identical to home cages and was placed in a photocell
frame, which had an array of beams in perpendicular directions
(SmartFrame; Kinder Scientiﬁc, Poway, CA). Beam breaks caused
by the mouse were cumulated for analysis, on a computer
interface.
Open Space Swim (OSS): This assay has been previously
described (Stone et al., 2008) and was used with minor
modiﬁcations, as a single session stress exposure. Mice were
individually placed in a standard rectangular shoebox
transparent plastic cage (19.7 cm width × 41.3 cm length ×
20.3 cm height), with water at 31 ± 1°C, at a depth of
approximately 13 cm. The swim surface area of the cage for
OSS used here was therefore ≈814 cm2. For comparison, the
standard FST test (not used here) provides an approximately 6fold smaller swim surface area (typically 13 cm diameter;
≈133 cm2) (Porsolt et al., 1977; Castagne et al., 2011).
Sessions (15-min long) were recorded with digital
videocameras, and analyzed by a trained observer, for “blind”
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scoring of duration of immobility. The camera was pointed
horizontally, at the surface level of the water. This allowed
visualization of movements above and below the surface.

Procedures
Locomotor activity: One to three days prior to experiments, mice
were habituated individually to locomotor cages, for a 60-min
session. Consecutive experimental sessions in the same mice
(90 min in duration) were separated by at least 72 h. Beam
breaks were quantiﬁed as a measure of locomotor activity,
over 15-min bins in the session.
Open Space Swim (OSS): A 1-day OSS procedure was carried out
(Stone et al., 2008). Each mouse was used only once, in a single 15min swim period. Immobility was deﬁned as having only movements
necessary to stay aﬂoat, for P2 s. After the test, the animal was
returned to home cage. The water was changed after 8 mice had
swum, or as needed to maintain water temperature. Immobility time
was timed cumulatively in 1-min bins, by a trained observer who was
“blinded” as to the treatment (i.e., vehicle or LY2795050). After
training, intra-rater correlation for repeated scoring of 8 separate 1min bins was high (Pearson r  0.97; p < 0.0001), as was inter-rater
correlation (Pearson r  0.93; p  0.001).

Design
Locomotor activity: Locomotor experiments were performed to
deﬁne basic KOR-antagonist effects of LY2795050, to be further
examined in the OSS. Experiments were carried out with a withinsubjects design, balanced for order. We determined the time course of
the antagonist effects of LY2795050 (0.32 mg/kg, or vehicle) in
preventing locomotor deﬁcits caused by U50,488 (10 mg/kg), in
males only. These dosing conditions were based on prior doseeffect studies, including determinations in both males and females
(Butelman et al., 2019; Butelman et al., 2021). LY2795050 (0.32 mg/kg
or vehicle) was therefore injected 15 min, 3 h, or 24 h prior to
U50,488 (10 mg/kg). Mice were placed into locomotor cages
immediately following U50,488 injection, for a 90-min session. In
a second study, a 10-fold smaller dose of LY2795050 (0.032 mg/kg or
vehicle) was injected as a 15 min pretreatment to U50,488
(10 mg/kg); this smaller LY2795050 was found to be inactive in
other assays (Butelman et al., 2019; Butelman et al., 2021).
Open space swim (OSS): OSS studies were performed with a
between-groups design; each mouse was used for a single session.
In the ﬁrst experiment, LY2795050 (0.32 mg/kg, or vehicle) was
administered as a 1-min pretreatment to OSS in males and
females. The second study examined the effects of the same
dose of LY2795050 (0.32 mg/kg, or vehicle), but with a longer
pretreatment time (15 min). Lastly, the effects of a 10-fold smaller
dose of LY2795050 (0.032 mg/kg, or vehicle) was studied, with a
15-min pretreatment before OSS.

FIGURE 1 | KOR-antagonist effects of LY2795050 pretreatment to
U50,488 in the locomotor activity assay (in males). Total locomotor counts are
shown for a 90-min session, starting immediately after injection of U50,488.
(A): Effect of LY2795050 (0.32 mg/kg or vehicle) given at different
pretreatment times (15 min, 3 h, or 24 h) before U50,488 (10 mg/kg). (B):
Effect of different doses of LY2795050 (0.032 and 0.32 mg/kg, or vehicle)
given 15 min before U50,488 (10 mg/kg).

each 15-min OSS session were also analyzed as 1-min bins, in order
to examine in greater detail the emergence of immobility over time.
This was done with a non-linear regression with an exponential
plateau growth curve (Graphpad Prism), with the following
parameters: YYmax -(Ymax-Ymin) * exp(-k*x), where Ymin and
Ymax are the minimum and maximum value of the curve,
respectively, “k” is the rate constant, and “x” is the time (1-min
bins). Since these were 1-min bins measuring immobility, Ymin was
constrained at 0 s, and the largest possible Ymax value was 60 s. A
lack of overlap in the 95%CI for the maximum plateau value (Ymax)
between LY2795050 and vehicle treatment was used as an indicator
of a signiﬁcant difference.

Statistics
Drugs

Graphpad Prism (version 9) software was used for statistical
analyses. Data for locomotor activity and immobility were
analyzed with repeated measures ANOVAs and Sidak’s or
Tukey’s post-hoc tests (including planned comparisons), or with
t-tests (p ≤ 0.05 level used as the criterion for signiﬁcance). Mixed
effects ANOVAs were used if there were missing data. Data for
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As mentioned above, doses of the KOR-antagonist LY2795050
and the KOR-agonist U50,488 were based on recent reports
(Butelman et al., 2019; Butelman et al., 2021). Thus,
0.32 mg/kg LY2795050 causes KOR-antagonist effects in
different assays (including a locomotor assay) in both male
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FIGURE 2 | Effect of 1-min pretreatment of LY2795050 (0.32 mg/kg, or vehicle) on immobility in the open space swim (15-min duration). (A) shows data in three
consecutive 5-min bins, analyzed by mixed model 2-way ANOVA, in males and females (the data were also analyzed in a 3-Way ANOVA; see Results). (B,C) show data
re-plotted as 1-min bins, in males and females respectively. The regression lines in (B) (males) shows exponential plateau growth curves (see Methods). The ﬁtted
maximum plateau for immobility in males was signiﬁcantly lower for LY2795050 versus vehicle (based on non-overlapping 95%CI). This regression could not be ﬁt
for panel C (females).

and female C57BL/6 J mice (Butelman et al., 2021). By contrast, a
10-fold smaller LY2795050 dose (0.032 mg/kg) is inactive
(Butelman et al., 2019; Butelman et al., 2021); see also
(Placzek et al., 2018). U50,488 (10 mg/kg) produces robust
decreases in locomotor activity in both male and female mice
(Paris et al., 2011; Butelman et al., 2021). Therefore controls for
these conditions were not carried out here, in order to limit the
total number of mouse experiments. Non-radiolabeled
LY2795050 (3-chloro-4-(4-(((2S)-2-pyridin-3-ylpyrrolidin-1-yl)
methyl) phenoxy)benzamide)) (Naganawa et al., 2015; 2015b;
Placzek et al., 2018) was purchased from BOC Sciences (Shirley,
NY). LY2795050 was dissolved in 5% ethanol/10% Tween 80/85%
sterile water, by volume. U50,488 was (Sigma-Aldrich) was

Frontiers in Pharmacology | www.frontiersin.org

dissolved in sterile water. LY2795050 and U50,488H were used
within approximately 2 h of being in solution. Each experiment
had its own appropriate vehicle condition. Mice were injected i.p.
(volume of 10 ml/kg).

RESULTS
Locomotor Activity
LY2795050, at a dose that is devoid of direct locomotor effects
(0.32 mg/kg) (Butelman et al., 2021), prevented the locomotor
depressant effects of U50,488 (10 mg/kg) when given as a 15 min,
but not 3 h or 24 h, pretreatment (only males studied; Figure 1A).
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for maximum immobility after LY2795050 (29.7 s; 95%CI:
25.8–35.6) was lower than after vehicle (44.2 s; 95%CI:
37.4–58.3).
In females, no effect of LY2795050 was detected, in a similar 2way ANOVA for 5-min bins, neither for treatment [F (1,14) 
2.45; ns], nor time bin [F (2,28)  1.06; ns], or their interaction
[F(2,28)  0.4; ns] (Figure 2A). A non-linear ﬁt could not be
adequately achieved with the 1-min bin data in females
(Figure 2C).
15-min pretreatment with LY2795050 (0.32 mg/kg): When
administered with a slightly longer (15 min) pretreatment,
LY2795050 decreased immobility in both males and females
(Figure 2). As above, data for 3 consecutive 5-min bins were
initially analyzed with a 3-way mixed model ANOVA (treatment
X sex X time bin) (Figure 3A). In this 3-way ANOVA, there was a
main effect of treatment [F (1, 33)  26.46; p < 0.0001] and of time
bin [F (1.73, 55.30)  9.86; p  0.0004], but no main effect of sex.
There no signiﬁcant interactions between these three variables
(not shown). Likewise, there were no signiﬁcant differences
across sex, either in vehicle or LY2795050 conditions (Tukey’s
tests).
We then further examined effects of LY2795050 in males and
females separately, as above. In males, a 2-way mixed-effects
ANOVA in three consecutive 5-min time bins (treatment X
time bin) detected signiﬁcant main effect of treatment [F (1, 44)
 21.97; p < 0.0001] and time bin [F (1.50, 33.07)  5.87; p  0.012],
but no interaction [F (2, 44)  2.65; ns] (Figure 3A). A planned
comparison with Sidak’s test showed a signiﬁcant decrease in
immobility in the LY2795050-pretreated group compared to
vehicle, in the last two time bins of the OSS (i.e., 6–10 min and
11–15 min bins). As above, a non-linear regression was used to
examine immobility data in greater detail (1-min time bins)
(Figure 3B, in males). This regression indicated a signiﬁcantly
lower maximum plateau value (Ymax) for immobility in the
LY2795050 versus the vehicle group. Thus, the best ﬁt value for
maximum immobility after LY2795050 (19.7 s; 95%CI: 17.5–22.1)
was lower than after vehicle (35.3 s; 95%CI: 31.8–39.8).
In the females, a similar mixed-effects 2-way ANOVA over 5min time bins (treatment X time bin) showed a main effect of
treatment [F (1, 18)  8.72; p  0.0085] and time bin [F (1.76,
30.81)  5.61; p  0.011], but no interaction [F (2, 35)  0.095; ns]
(Figure 3A). Planned comparisons with Sidak’s test did not detect
that any speciﬁc time bin was signiﬁcantly different in LY2795050
versus vehicle conditions. A non-linear regression on the 1-min
time bins in the females did not detect a difference in the
maximum immobility in the LY2795050- versus the vehicletreated mice (as shown by overlapping 95%CI) (Figure 3C).
Thus, the best ﬁt value for maximum immobility after LY2795050
(20.1 s; 95%CI: 16.8–25.6) was not different than after vehicle
(28.6 s; 95%CI: 25.3–32.9).
15-min pretreatment with a 10-fold smaller dose of
LY2795050 (0.032 mg/kg): At a 10-fold smaller dose
(0.032 mg/kg) and with a 15-min pretreatment time,
LY2795050 did not decrease immobility in the OSS, in either
males or females. For example, in the last 5-min time bin of the
session (i.e., 11–16 min), LY2795050- and vehicle-treated groups
were not different, either in males or females (Table 1).

A 2-way ANOVA [pretreatment (LY2795050 or vehicle) X
pretreatment time] found a main effect of both pretreatment
(F (1, 7)  21.73; p  0.0023) and pretreatment time [F (2, 14) 
20.85; p < 0.0001] but no interaction [F (2, 14)  2.572; NS]. A
Sidak’s multiple comparisons test determined that LY2795050
pretreatment signiﬁcantly reduced U50,488-induced locomotor
deﬁcits compared to vehicle pretreatment, only at the shortest PT
time (15 min).
The KOR-antagonist effect of LY2795050 in the locomotor
assay was dose-dependent, as a 10-fold smaller dose
(0.032 mg/kg), given as a 15 min pretreatment to U50,488, did
not prevent U50,488-induced locomotor deﬁcits (Figure 1B). A
2-way ANOVA (pretreatment X LY2795050 dose) revealed main
effects of pretreatment [F (1, 13)  7.351; p  0.0178] and of
LY2795050 dose [F (1, 13)  4.79; p  0.047]. There was no
pretreatment X dose interaction [F (1, 13)  1.509; NS]. Planned
comparisons with Sidak’s tests revealed signiﬁcant differences
between the larger dose of LY2795050 (0.32 mg/kg) pretreatment
and its vehicle condition, but not for the smaller dose
(0.032 mg/kg) (Figure 1).

Open Space Swim (OSS)
1-min pretreatment with LY2795050 (0.32 mg/kg): A 1-min
pretreatment with LY2795050 (0.32 mg/kg) decreased
immobility in the OSS session (15-min in duration) compared
to vehicle, in males but not in females (Figure 2). In order to
examine sex differences, data for 3 consecutive 5-min bins were
analyzed with a 3-way mixed model ANOVA (treatment X sex X
time bin, with repeated measures on the last variable)
(Figure 2A). In this 3-way ANOVA, there was a main effect
of treatment [F (1, 27)  6.10; p  0.02], of sex [F (1, 27)  21.00;
p < 0.0001] and of time bin [F (1.67,44.29)  9.92; p  0.0006].
There was also a signiﬁcant interaction between sex and time bin
[F (2, 53)  6.20; p  0.0038], but no other interaction was
signiﬁcant (not shown). Tukey’s post-hoc tests were used to
examine sex differences. In the ﬁrst two time bins (i.e., 1-5
and 6–10 min), there were no differences between males and
females, either for the vehicle or LY2795050 conditions. However,
in the third time bin (11–15 min), males had signiﬁcantly greater
immobility scores under the vehicle condition, compared to
females (Tukey test; p  0.0043). There were no sex
differences in the LY2795050 condition.
In order to further explore the effects of LY2795050, we then
analyzed the data separately for males and females. In males, a
mixed-effects 2-way ANOVA of three consecutive 5-min time
bins (treatment X time bin) detected a main effect of time bin [F
(1.58, 19.76)  14.50; p  0.0003] but not of treatment [F (1, 13) 
3.87; ns] or their interaction [F (2,25)  1.50; ns] (Figure 2A). A
planned comparison with Sidak’s test showed a signiﬁcant
decrease in immobility only in the last bin (11–15 min), in the
group pretreated with LY2795050 compared to vehicle. A nonlinear regression was carried out to examine maximum
immobility in greater detail across the OSS session
(consecutive 1-min time bins; see Methods) (Figure 2B). This
regression indicated a signiﬁcantly lower maximum plateau value
(Ymax) for immobility in the LY2795050 versus the vehicle group,
as denoted by a lack of overlap in 95%CI. Thus, the best ﬁt value
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FIGURE 3 | Effect of 15-min pretreatment of LY2795050 (0.32 mg/kg, or vehicle) on immobility in the open space swim (15-min duration). (A) shows data in three
consecutive 5-min bins, analyzed by mixed model 2-way ANOVA, in males and females (the data were also analyzed in a 3-Way ANOVA; see Results). (B,C) show data
re-plotted as 1-min bins, in males and females respectively. The regression lines in (B) (males) show exponential plateau growth curves; the ﬁtted maximum plateau for
immobility is signiﬁcantly lower for LY2795050 versus vehicle. In (C) (females), the ﬁtted maximum plateau is not signiﬁcantly different for LY2795050 versus vehicle.

TABLE 1 | Immobility in the last 5-min bin (i.e., 11–15 min) of the open space swim session after a 10-fold smaller dose of LY27950590 (0.032 mg/kg).

Males (n  8/group)
Females (n  8/group)

0.032 mg/kg LY2795050

Vehicle

Mean (±95%CI)

Mean (±95%CI)

107.5 (52.7–162.4)
107.2 (56.2–158.1)

130.1 (89.4–170.8)
69.2 (33.4–105.0)

DISCUSSION

t (14)  0.78; ns
t (14)  1.44; ns

U50,488-induced locomotor deﬁcits when administered as a
15-min pretreatment, but was ineffective at longer
pretreatments (3 and 24 h, determined only in males). This is
consistent with the effectiveness of LY2795050 (0.32 mg/kg),
previously determined in locomotor activity studies in both
male and female mice (Butelman et al., 2021). The
effectiveness of this dose of LY2795050, its rapid onset and
relatively short duration of action are also consistent with
prior data in rodents, in other assays (Placzek et al., 2018;
Butelman et al., 2019). Other novel KOR antagonists, such as
the congener LY2444296 (also known as FP3FBZ) (Melief et al.,

This study shows that the short-acting KOR-antagonist
LY2795050 can produce very rapid-onset anti-immobility
effects in a model of acute stress exposure. The study also
shows that apparent sex differences in the effects of KORantagonists may be due to the speciﬁc stress paradigm used
(Laman-Maharg et al., 2018; Williams et al., 2018; Diester
et al., 2019; Butelman et al., 2021).
Initial examinations in the locomotor activity assay
demonstrated that LY2795050 (0.32 mg/kg) prevented
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2011; Valenza et al., 2017) have slightly longer durations of action
than LY2795050 (Butelman et al., 2019). Duration of KOR
antagonist action has been correlated to activation of c-Jun-Nterminal kinase-1 (JNK1) (Melief et al., 2011). The effects of
LY2795050 on JNK1 activity have not been reported, to our
knowledge.
We found for the ﬁrst time that a very short (1 min)
pretreatment with LY2795050 (0.32 mg/kg) was able to
decrease immobility in the OSS assay (15-min duration), but
only in male, but not female mice. Growth curve analysis over 1min bins revealed that LY2795050 was able to decrease maximal
immobility, which was observed typically in the last 5 min of the
swim exposure.
Since KOR-antagonist effects of LY2795050 (0.32 mg/kg) were
detected here in the locomotor assay with a 15-min pretreatment
in males (and previously in females also) (Butelman et al., 2021),
this pretreatment time was then studied in the OSS assay. With
this slightly longer pretreatment, LY2795050 (0.32 mg/kg) caused
a decrease in immobility in both male and female mice, when
examined over the three consecutive 5-min bins of OSS stress
exposure. Overall, these results indicate that short-acting KORantagonists such as LY2795050 can also produce anti-stress
effects in females, depending on the assay, consistent with
other reports (Williams et al., 2018; Jacobson et al., 2020c).
Intriguingly, pretreatment with a different short-acting KOR
antagonist prevented the effects of social defeat stress in both
male and female California mice, whereas administration after
the stress was ineffective (Williams et al., 2018). Potential sex
differences in the behavioral effects of novel KOR-antagonists
have been studied under a limited set of conditions (Williams
et al., 2018; Jacobson et al., 2020a; Jacobson et al., 2020c;
Butelman et al., 2021), but sexual dimorphism in the KOR/
dynorphin system has been previously reported (Chartoff and
Mavrikaki, 2015; Becker and Chartoff, 2019; Jacobson et al.,
2020c).
The effects of LY2795050 in the OSS were dose-dependent,
since a 10-fold smaller dose (0.032 mg/kg) did not affect
immobility. This is consistent previous ﬁndings that this
smaller dose of LY2795050 does not exhibit KOR-antagonist
effects in other assays mice (Butelman et al., 2019; Butelman et al.,
2021).
Limitations and methodological considerations: The largest
dose of LY2795050 alone (0.32 mg/kg) does not have locomotor
effects in either male or female C57BL/6 J mice (Butelman et al.,
2021). Therefore the anti-immobility effects of LY2795050 in the
OSS are not simply due to a confound with locomotor effects.
The time-dependent increase of immobility within a session of
swim stress has been examined in the standard FST, previously
(Castagne et al., 2009; Chen et al., 2015; Molendijk and de Kloet,
2019). In the standard FST in mice, immobility is typically
reported for the last 4 min of a 6-min swim (Porsolt et al.,
1977; Castagne et al., 2011). In order to examine the increase
of immobility across the full 15-min OSS herein, we selected an
exponential plateau growth curve, for nonlinear regression
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analysis. This regression model is appropriate for analysis of
time series data where a maximum plateau is observed (as occurs
in the OSS session). Using these regression analyses, we detected a
LY2795050-induced decrease in the maximum plateau of
immobility in males, but not in females. It cannot be excluded
that a different regression model, or an increase in number of
mice per group may have yielded slightly different results.
Likewise, it cannot be excluded that there was a “ﬂoor” effect
on immobility scores in the OSS in female mice.
In this study, male versus female differences in the effects of
LY2795050 were examined in gonadally intact adult mice. Larger
doses of LY2795050 (i.e., >0.32 mg/kg) were not studied, because
they also exhibit MOR-antagonist effects (Butelman et al., 2019).
Future studies could determine whether the subtle sex differences
observed in the OSS were due to hormonal or organizational
effects (Craft and Bernal, 2001; Land et al., 2009; Chartoff and
Mavrikaki, 2015).
KOR and endogenous dynorphin function can be regulated by
stress exposure in several brain areas and pathways (Shirayama
et al., 2004; Carlezon et al., 2006; Rosa et al., 2018). Future studies
could determine which brain pathway(s) mediate the rapid antistress effects of a systemically administered KOR-antagonist,
such as LY2795050.
Conclusion: This is the ﬁrst study to examine the effects of a
KOR-antagonist in the open space swim stress (OSS) procedure.
Very rapid onset anti-stress effects of LY2795050 were detected,
more robustly in males than in females. This proﬁle may be of
potential interest in the modulation of the behavioral and
neurobiological consequences of acute stress exposure, in
translational models, and possibly for medication development.
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